AI Analysis | Feedback

1. The Moderna of oncology, specializing in targeted radiopharmaceuticals.

2. Like Novartis's radiopharmaceutical division, but as an independent, focused company.

3. An early-stage Genentech, focused on precision radiopharmaceuticals for cancer.

AI Analysis | Feedback

• AKTIS-101: Aktis Oncology's lead investigational drug candidate, designed as a tumor-localized innate immune activator to stimulate anti-tumor responses in solid tumors.
• TLIIA Platform (Tumor-Localized Innate Immune Activator Platform): This proprietary technology is Aktis Oncology's core asset, enabling the discovery and development of novel drug candidates that selectively activate innate immune pathways directly within tumors.

AI Analysis | Feedback

Aktis Oncology (AKTS) is a clinical-stage biotechnology company focused on developing novel, targeted alpha radiopharmaceuticals for the treatment of solid tumors.

Aktis Oncology does not currently have major customers as it does not have any approved products available for sale on the market.

As a clinical-stage company, its primary activities involve research and development, conducting clinical trials, and securing financing to advance its pipeline. The company's operations are funded primarily through equity financing (e.g., venture capital, public stock offerings) and potential future strategic collaborations or partnerships, rather than through product sales.

Should Aktis Oncology successfully develop and commercialize any of its product candidates in the future, its ultimate customer base would primarily involve sales to healthcare providers for use in individuals. These categories would typically include:

1. Healthcare Providers: Hospitals, clinics, and individual oncologists who prescribe and administer cancer therapies to patients.
2. Patients with Specific Cancers: Individuals diagnosed with the types of solid tumors that Aktis Oncology's therapies are designed to treat.
3. Healthcare Payers: Government health programs (e.g., Medicare, Medicaid) and commercial insurance companies that cover the costs of prescription drugs and treatments for eligible patients.

However, these represent potential future customer categories upon successful product approval and commercialization, not current major customers.

AI Analysis | Feedback

AI Analysis | Feedback

Matthew Roden, PhD. President, Chief Executive Officer

Matthew Roden serves as the President and Chief Executive Officer of Aktis Oncology and is also a member of the company's Board of Directors. He is an Executive Partner at MPM BioImpact, an investment firm that founded and incubated Aktis Oncology. Prior to his role at Aktis Oncology and MPM, Dr. Roden held senior leadership positions at Bristol Myers Squibb, where he was SVP and Head of Enterprise Strategy, Head of Strategic Corporate Development (responsible for mergers and acquisitions), and Head of Global BD Assessment. During his time there, he led business development transactions cumulatively valued at over $125 billion. Before his corporate career, he worked as a leading equity research analyst covering the global biotechnology sector at UBS and J.P. Morgan. He also serves on the Boards of Directors of ORNA Therapeutics and a stealth NewCo, and previously chaired Turmeric Acquisition Corporation.

Kyle Kuvalanka. Chief Financial Officer

Kyle Kuvalanka is the Chief Financial Officer of Aktis Oncology, bringing over 20 years of senior leadership experience in the biopharmaceutical sector. He previously served as CFO and Chief Business Officer (CBO) at ROME Therapeutics and as CFO and Chief Operating Officer (COO) at Goldfinch Bio, both privately-held companies. Before these roles, Mr. Kuvalanka was COO at Syros Pharmaceuticals and CBO at Blueprint Medicines, where he was instrumental in building and leading finance and business functions and guiding both companies through their initial public offerings. Earlier in his career, he held Vice President positions in Business Development, Corporate Strategy, Alliance Management, and Investor Relations at Millennium Pharmaceuticals, a Takeda Oncology Company. Mr. Kuvalanka has raised over $700 million in capital and led numerous transactions for both public and private clinical and commercial-stage companies.

Akos Czibere, MD, PhD. Chief Medical Officer

Akos Czibere serves as the Chief Medical Officer at Aktis Oncology.

Paul L. Feldman, PhD. Chief Scientific Officer

Paul L. Feldman is the Chief Scientific Officer at Aktis Oncology. Before joining Aktis Oncology, Dr. Feldman was the Head of Discovery and Translational Medicine at Intarcia Therapeutics.

Shulamit Ron-Bigger, PhD. Chief Operating Officer

Shulamit Ron-Bigger holds the position of Chief Operating Officer at Aktis Oncology.

AI Analysis | Feedback

1. Clinical Development and Regulatory Risk: As a clinical oncology company, Aktis Oncology's success is heavily dependent on the successful outcome of its clinical trials and subsequent regulatory approvals for its drug candidates. The development of its lead candidate, [225Ac]Ac-AKY-1189, is currently in early-stage (Phase 1b) trials with preliminary results not expected until the first quarter of 2027. The inherent risks associated with clinical trials, including the possibility of unfavorable results or failure to meet regulatory requirements, pose a significant threat to the business.
2. Financial Viability and Operating Losses: Aktis Oncology has recorded substantial net losses since its inception in 2020. For the 12 months ending September 30, 2025, the company reported a net loss of $-60.65 million. For the nine months ending September 30, 2025, it reported a $48.6 million net loss. The company operates in a capital-intensive sector, and its ability to continue funding its research, development, and clinical programs will rely on its ability to raise additional capital, such as through its ongoing IPO, and eventually generate significant revenue, which is still years away from potential product commercialization.
3. Limited Pipeline and Early-Stage Nature: The company's pipeline consists of drug candidates predominantly in early stages of development. Its lead candidate is in Phase 1b, and another candidate, Ac-AKY-2519, is planned for an IND filing in 2026. The business's future prospects are largely tied to the success of these few, early-stage assets, which carries a higher risk profile compared to companies with more diversified or advanced pipelines.

AI Analysis | Feedback

The recent acquisitions of radiopharmaceutical companies, particularly those focused on alpha-emitters, by large pharmaceutical companies represent a clear emerging threat. For instance, AstraZeneca acquired Fusion Pharmaceuticals (focused on alpha-emitters) and Bristol Myers Squibb acquired RayzeBio (also focused on radiopharmaceuticals including alpha-emitters). This signifies a substantial increase in big pharma investment and resources entering Aktis Oncology's core therapeutic modality. This influx of capital and development power from well-established, globally-reaching pharmaceutical giants intensifies the competitive landscape. Aktis, as a smaller, clinical-stage company, faces the emerging challenge of competing for talent, clinical trial sites, market differentiation, and ultimately market share against vastly better-resourced and more experienced competitors within its niche.

AI Analysis | Feedback

The addressable market for Aktis Oncology's main products and services, which are targeted radiopharmaceuticals, is projected to be substantial.

• The total addressable market for radiopharmaceuticals is projected to exceed $26 billion in sales by 2032.
• The therapeutic segment of this market is estimated to achieve a total addressable market of $25 billion to $60 billion post-2030.

These market size projections are generally considered global in context, as they refer to the overall radiopharmaceutical market. Aktis Oncology is developing next-generation alpha-emitting radioconjugates using proprietary miniproteins to target solid tumors, with lead candidates such as AKY-1189 (targeting Nectin-4) and AKY-2519 (targeting B7-H3). The company aims to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Aktis Oncology (AKTS) over the next 2-3 years:

1. Milestone Payments from Eli Lilly Collaboration: Aktis Oncology has a strategic collaboration agreement with Eli Lilly that includes potential milestone payments up to $1.1 billion. The achievement of these clinical and regulatory milestones as the partnered programs advance will be a significant driver of revenue growth.
2. Advancement and Potential Commercialization of Lead Candidate (AKY-1189): The company's lead radiopharmaceutical candidate, [225Ac]Ac-AKY-1189, is currently in a Phase 1b trial targeting Nectin-4 expressing tumors across multiple cancer types, including urothelial, breast, lung, colorectal, and cervical cancers. Positive clinical trial results and subsequent progression toward regulatory approvals and eventual market launch would be a primary revenue driver for Aktis Oncology.
3. Progression of Second Pipeline Candidate (AKY-2519): Aktis Oncology plans to advance its second program, [225Ac]Ac-AKY-2519, which targets B7-H3 expressing solid tumors (such as prostate and lung cancers), into a Phase 1b trial in the second half of 2026. Successful clinical development of this candidate would generate additional milestone payments and lay the groundwork for a second potential commercial product.
4. Expansion into Broader Cancer Indications and Patient Populations: Aktis Oncology aims to leverage its proprietary miniprotein radioconjugate platform to address large patient populations and various solid tumor types not adequately served by existing radiopharmaceutical technologies. This strategy of expanding the scope of treatable cancers with its innovative approach represents a significant opportunity for market penetration and revenue growth.
5. Leveraging Proprietary Miniprotein Radioconjugate Platform for New Product Development: The company's unique miniprotein radioconjugate platform is designed to develop next-generation alpha-emitting radioconjugates with improved tumor penetration and clearance characteristics. Continued innovation and development of new product candidates from this platform could lead to additional strategic collaborations and a robust pipeline, fueling long-term revenue expansion.

AI Analysis | Feedback

Share Issuance

• Aktis Oncology filed for an initial public offering (IPO) in December 2025, aiming to raise up to $100 million.
• The company plans to sell new shares as part of the IPO.
• Proceeds from the IPO are designated to advance its lead candidate, [225Ac]Ac-AKY-1189, through a Phase 1b trial, progress a second program, [225Ac]Ac-AKY-2519, into a Phase 1b trial in the second half of 2026, and for general working capital and corporate purposes.

Inbound Investments

• Aktis Oncology has raised a total of $336 million across three funding rounds before its IPO filing.
• The company closed an oversubscribed Series B financing round in September 2024, securing $175 million. This round was led by RA Capital Management, co-led by RTW Investments and Janus Henderson Investors, and included participation from existing strategic investors such as Bristol Myers Squibb, Eli Lilly and Company, and MRL Ventures Fund. The financing implied a purchase price of $4.00 per share for 43.75 million shares of preferred stock.
• In early 2024, Aktis Oncology entered a collaboration agreement with Eli Lilly for cancer-targeting radiopharmaceutical drugs, which included an upfront payment of $60 million and potential milestone payments totaling up to $1.1 billion.

Capital Expenditures

• Over the last 12 months, Aktis Oncology recorded capital expenditures of -$7.66 million.
• The company is investing in establishing an internal cGMP (current Good Manufacturing Practice) facility, which is anticipated to be operational in 2026.
• These capital expenditures are focused on building a hybrid manufacturing and supply chain, encompassing multiple 225Ac isotope supply agreements.